**
Overview
Diabetes mellitus, often simply called diabetes, comprises a group of metabolic diseases in which the body cannot maintain normal glucose homeostasis. Glucose is the primary fuel for cells, and its regulation depends on the hormone insulin, secreted by the pancreatic β‑cells. In type 1 diabetes, an autoimmune attack destroys these β‑cells, resulting in little or no insulin. In type 2 diabetes, the majority of cases worldwide, the pancreas initially produces insulin but peripheral tissues become insulin‑resistant, forcing the organ to work harder until it eventually fails. A third, less common form—gestational diabetes—arises during pregnancy and usually resolves after delivery, though it raises future risk for both mother and child. Classic clinical features are the “three Ps”: polydipsia (excessive thirst), polyuria (frequent urination), and polyphagia (increased hunger), often accompanied by unintentional weight loss, blurred vision, and fatigue. Diagnosis relies on laboratory criteria such as fasting plasma glucose ≥126 mg/dL, a 2‑hour oral glucose tolerance test ≥200 mg/dL, or an HbA1c ≥6.5 %.If left untreated, chronic hyperglycemia damages blood vessels and nerves, precipitating a spectrum of microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary artery disease, stroke, peripheral arterial disease) complications. These sequelae account for the disease’s high mortality: roughly 4.2 million deaths per year worldwide, with about 1.5 million directly attributable to untreated or poorly controlled diabetes. Early detection, lifestyle modification, and individualized pharmacotherapy are essential to prevent or delay these outcomes. Anyone experiencing persistent symptoms or at high risk (e.g., family history, obesity, sedentary lifestyle) should seek professional medical evaluation promptly.
History/Background
The earliest written record of diabetes dates to an Egyptian papyrus (c. 1500 BC) describing “excessive urination.” The term “diabetes” (Greek for “siphon”) was coined by the physician Aretaeus of Cappadocia in the 2nd century AD, while Madhava of India noted the sweet taste of urine in the 6th century. In 1869, Paul Langerhans identified the pancreatic islets (now called Langerhans islets) that later proved to be the source of insulin. The breakthrough came in 1921–1922 when Frederick Banting, Charles Best, and John Macleod isolated insulin, enabling life‑saving therapy for type 1 diabetes.The mid‑20th century saw the rise of type 2 diabetes as a public health issue, linked to urbanization, dietary changes, and obesity. The World Health Organization (WHO) officially recognized diabetes as a global epidemic in the 1990s, prompting the first International Diabetes Federation (IDF) conference in 1999. Since then, diagnostic criteria have been refined (e.g., introduction of HbA1c as a diagnostic test in 2010) and novel drug classes—metformin, GLP‑1 receptor agonists, SGLT2 inhibitors—have expanded therapeutic options.
Key Information
- Classification: Type 1, Type 2, Gestational, and specific monogenic forms (MODY, neonatal diabetes). - Epidemiology: Over 537 million adults (≈ 10 % of the global population) live with diabetes; prevalence is rising fastest in low‑ and middle‑income countries. - Pathophysiology: - Insulin deficiency: autoimmune β‑cell destruction (type 1) or β‑cell exhaustion (type 2). - Insulin resistance: impaired signaling in muscle, adipose, and hepatic tissue, often driven by excess adiposity and inflammatory cytokines. - Diagnostic thresholds: Fasting glucose ≥126 mg/dL, 2‑hour OGTT ≥200 mg/dL, HbA1c ≥6.5 %, or random glucose ≥200 mg/dL with classic symptoms. - Management pillars: 1. Lifestyle: balanced diet (Mediterranean or DASH patterns), regular aerobic and resistance exercise, weight control. 2. Pharmacotherapy: metformin first‑line for type 2; insulin for type 1 and advanced type 2; adjunct agents (SGLT2 inhibitors, GLP‑1 agonists) for cardiovascular/renal protection. 3. Monitoring: self‑monitoring of blood glucose (SMBG), periodic HbA1c, blood pressure, lipid profile, and screening for complications (annual retinal exam, urine albumin, foot exam). - Complications: - Microvascular: diabetic retinopathy (leading cause of blindness), diabetic nephropathy (major cause of end‑stage renal disease), peripheral neuropathy (risk of foot ulcers). - Macrovascular: accelerated atherosclerosis, increased risk of myocardial infarction and stroke. - Prevention: Primary prevention focuses on obesity reduction, physical activity, and dietary quality; secondary prevention emphasizes early detection and tight glycemic control.Significance
Diabetes mellitus is a public health priority because it intersects with virtually every organ system and amplifies the burden of cardiovascular disease, the leading cause of death worldwide. Economically, the disease imposes staggering costs—estimated at US $966 billion in 2021—through direct medical expenses and lost productivity. The advent of newer drug classes that confer cardiorenal protection has reshaped treatment algorithms, underscoring the importance of a multidisciplinary approach involving endocrinologists, primary care physicians, dietitians, diabetes educators, and mental‑health professionals.Beyond the clinical realm, diabetes drives research innovation: continuous glucose monitoring (CGM), automated insulin delivery (“artificial pancreas”), and gene‑editing therapies for monogenic forms are rapidly moving from bench to bedside. Public‑health initiatives such as the WHO’s Global Diabetes Compact aim to halve premature deaths from diabetes by 2030, emphasizing early screening, equitable access to medicines, and health‑promoting policies.
For anyone suspecting diabetes or managing the condition, regular follow‑up with a qualified health professional is essential to tailor therapy, monitor for complications, and adjust lifestyle measures. Early, evidence‑based intervention can dramatically improve quality of life and longevity.
INFOBOX:
- Name: Diabetes mellitus
- Type: Chronic endocrine/metabolic disorder
- Date: First clinical description c. 1500 BC; modern insulin therapy 1922
- Location: Worldwide (global prevalence)
- Known For: Persistent hyperglycemia, insulin deficiency or resistance, and systemic complications
TAGS: diabetes, insulin, hyperglycemia, type 1 diabetes, type 2 diabetes, metabolic disease, chronic illness, public health
